Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04460703 · ClinicalTrials.gov registry record · NA
COVID-19 Vaccine Messaging, Part 1
A NA study, sponsored by Yale University.
- Completed
- Registry status
- NA
- Development phase
- 4,000
- Enrollment target
NCT04460703 is a NA study that has completed, run by Yale University. The registered enrollment target is 4,000 participants.
The verdict
NCT04460703, a NA study, has completed, sponsored by Yale University.
- COMPLETED
- Registry status
- NA
- Development phase
- 4,000 participants
- Enrollment target
Study Summary
This study tests different messages about vaccinating against COVID-19 once the vaccine becomes available. Participants are randomized to 1 of 12 arms, with one control arm and one baseline arm. We will compare the reported willingness to get a COVID-19 vaccine at 3 and 6 months of it becoming available between the 10 intervention arms to the 2 control arms. Study participants are recruited online by Lucid, which matches census based sampling in online recruitment.
Interventions
- OTHER Control message
- OTHER Baseline message
- OTHER Personal freedom message
- OTHER Economic freedom message
- OTHER Self-interest message
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4,000 participants |
| Start Date | 2020-07-03 |
| Est. Completion | 2020-07-08 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04460703
The ClinicalTrials.gov registry entry for NCT04460703 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 4,000 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Control message is the first listed.
NCT04460703 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04460703 about?
NCT04460703 is a clinical study titled "COVID-19 Vaccine Messaging, Part 1". This study tests different messages about vaccinating against COVID-19 once the vaccine becomes available. Participants are randomized to 1 of 12 arms, with one control arm and one baseline arm. We will compare the reported willingness to get a COVID-19 vaccine at 3 and 6 months of it becoming avail...
What is the current status of trial NCT04460703?
This trial is currently completed. It is a NA study. The enrollment target is 4,000 participants. The study started on 2020-07-03. Estimated completion is 2020-07-08.
What interventions are being tested in trial NCT04460703?
The interventions under investigation include: Control message (OTHER), Baseline message (OTHER), Personal freedom message (OTHER), Economic freedom message (OTHER), Self-interest message (OTHER).
Who is sponsoring clinical trial NCT04460703?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.